Clinical Trials
12 trialsNCT05392608 2026-05-22
SEQUEL-Breast
Borstkanker Onderzoek Groep
Phase 2 Active not recruiting
NCT03683277 2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2 Terminated
NCT00019097 2024-03-04
Vaccine Therapy in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019695 2024-03-04
Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00020202 2024-03-04
FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00019760 2023-10-31
Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01135537 2019-11-04
Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants
The Hospital for Sick Children
Phase 2 Terminated
NCT00004437 2015-03-25
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00004688 2015-03-25
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
FDA Office of Orphan Products Development
Phase 2 Completed
NCT00017680 2008-06-09
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
Office of Rare Diseases (ORD)
Phase 2 Completed
NCT00004659 2005-06-24
Phase II Randomized Study of Stereotactic Radiosurgery Plus Fractionated Whole-Brain Radiotherapy Vs Fractionated Whole-Brain Radiotherapy Alone for Multiple Primary or Metastatic Brain Tumors
Office of Rare Diseases (ORD)
Phase 2 Unknown